BioCryst Pharmaceuticals
BCRX
115 hedge funds and large institutions have $283M invested in BioCryst Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 35 reducing their positions, and 17 closing their positions.
453% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $185K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
6% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 35
1% less funds holding
Funds holding: 116 → 115 (-1)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
1.42% less ownership
Funds ownership: 90.83% → 89.41% (-1.4%)
25% less capital invested
Capital invested by funds: $380M → $283M (-$96.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.1M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$7.77M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$5.06M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$3.18M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$10.9M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.55M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$5.48M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$5.15M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$4.11M |
BCRX Hedge Fund Activity: Q3 2019 in Review
115 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2019, worth a combined $283M — down 25% from $380M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of BCRX and 16 opened new positions — a net loss of 1 holder — while 35 trimmed existing stakes and 37 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $10.1M. The largest seller was Deerfield Management, cutting an estimated $10.9M.
- 115 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2019, down from 116 in Q2 2019.
- Funds reported $283M of BioCryst Pharmaceuticals stock for Q3 2019, down 25% quarter-over-quarter.
- 16 funds opened new BioCryst Pharmaceuticals positions in Q3 2019 and 17 closed out, a net change of -1 holder.
- The largest BioCryst Pharmaceuticals buyer in Q3 2019 was Point72 Asset Management, an estimated $10.1M added.
- The largest BioCryst Pharmaceuticals seller in Q3 2019 was Deerfield Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q3 2019.